Home Tags AACR

Tag: AACR

Phase I Trial of SGN-CD352A in Relapsed or Refractory Multiple Myeloma...

This week the first patient enrolled in a multi-center phase I clinical trial of SGN-CD352A for the treatment of patients with relapsed or refractory...

Best ADC Platform Technology Awarded to Mersana Therapeutics

This week, during the 7th World ADC Conference in San Diengo, Mersana Therapeutics, a biotechnology company focused on discovering and developing a pipeline of...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

CytomX and AbbVie Jointly Develop and Commercialize Probody-drug Conjugates Directed...

Antibody-drug conjugates or ADCs combine the cytotoxic potential of chemotherapeutic drugs with the specificity of monoclonal antibodies.  One of the critical parameters effecting the efficacy,...

Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...

During the annual meeting of the American Association for Cancer Research (AACR) being held  April 16 - 20, 2016 in New Orleans, LA, Celldex...

Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...

The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...

OncoSec Medical’s ImmunoPulse IL-12 Primes Patients for an Enhanced Response to...

Melanoma is one of the most dangerous forms of skin cancer.  Based on recent data from the American Cancer Society, the disease accounts for...

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...

Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...

XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors

Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models.The...

AACR 2016: Companion and Complementary Diagnostics

Over the last decade, Targeted Therapies, Personalized and Precision Medicine have become part of our vocabulary, representing a new way of thinking in how...